Drug Trial Radar · NCT06079476
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Oct 30, 2023
Primary completion
Oct 18, 2025
Study completion Oct 18, 2025
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to characterize safety and tolerability of romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in India.
Conditions
- Postmenopausal Osteoporosis
Interventions
RomosozumabDrug
Single-use prefilled syringe for SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
- Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
- Number of Participants Who Experienced Clinically Significant Changes in Laboratory AssessmentsTime frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
- Number of Participants Who Experienced Clinically Significant Changes in Vital SignsTime frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Stavya Spine Hospital and Research Institute SSHRI
Ahmedabad, Gujarat, India
MS Ramaiah Medical College and Hospitals
Bangalore, Karnataka, India
King Edward Memorial Hospital And Seth Gordhandas Sunderdas Medical College
Mumbai, Maharashtra, India
Sancheti Institute for Orthopedics and rehabilitation
Pune, Maharashtra, India
Sir Ganga Ram Hospital
New Delhi, National Capital Territory of Delhi, India
Apollo Hospital
New Delhi, National Capital Territory of Delhi, India
Post Graduate Institute of Medical Education and Research
Chandigarh, Punjab, India
MGM Healthcare
Chennai, Tamil Nadu, India
Christain Medical College
Vellore, Tamil Nadu, India
King Georges Medical University
Lucknow, Uttar Pradesh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.